RAM
DMAAR

Readystate Asset Management’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Readystate Asset Management’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.43K Sell
31,200
-18,800
-38% -$1.94K ﹤0.01% 903
2026
Q1 		$2.75K Hold
50,000
– – ﹤0.01% 804
2025
Q4 		$7.89K Hold
50,000
– – ﹤0.01% 377
2025
Q3 		$10.9K Buy
+50,000
New +$9.29K ﹤0.01% 341

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Readystate Asset Management's DMAAR Position: Q2 2026 in Review

Readystate Asset Management reduced its Drugs Made In America Acquisition Corp Rights (DMAAR) stake by 38% in Q2 2026, selling an estimated $1.94K and leaving 31,200 shares worth $3.43K. The position accounts for ﹤0.01% of the portfolio, ranked #903.

Readystate Asset Management first reported a position in DMAAR in Q3 2025 and has held it in 4 quarters since. The position peaked at $10.9K in Q3 2025. 28 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

  • Readystate Asset Management held 31,200 shares of Drugs Made In America Acquisition Corp Rights worth $3.43K as of Q2 2026.
  • Readystate Asset Management sold 18,800 Drugs Made In America Acquisition Corp Rights shares in Q2 2026, an estimated $1.94K.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Readystate Asset Management's portfolio in Q2 2026, its #903 holding.
  • Readystate Asset Management first reported a position in Drugs Made In America Acquisition Corp Rights in Q3 2025 and has held it in 4 quarters since.
  • Readystate Asset Management's Drugs Made In America Acquisition Corp Rights position peaked at $10.9K in Q3 2025.
  • 28 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on Readystate Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.